This approach allows for the use of targeted treatments, such as gemtuzumab ozogamicin for core-binding factor AML, midostaurin for FLT3-mutated AML, CPX-351 for AML with myelodysplasia-related changes, and ivosidenib for IDH1-mutated AML. The gene discussed is IDH1; the disease is acute myeloid leukemia.